- Published on
Ophthalmology – Birdshot Chorioretinopathy
Birdshot chorioretinopathy is a rare, chronic, bilateral form of posterior uveitis characterized by distinctive cream-colored lesions at the level of the choroid. These lesions radiate outward from the optic nerve, resembling the scattered pattern of birdshot from a shotgun. The disease is strongly associated with the HLA-A29 allele, with over 90% of affected individuals testing positive, making it one of the strongest HLA-disease associations in medicine.
This condition primarily affects middle-aged adults, with an average onset around 50 years of age, and is more commonly seen in individuals of Caucasian descent. Both males and females are affected equally. Although the exact cause remains unclear, the disease is believed to be autoimmune in nature, likely involving a type IV hypersensitivity reaction targeting retinal or choroidal antigens.
Patients typically present with gradual, painless, bilateral visual decline. Common symptoms include floaters, nyctalopia (night vision difficulty), photopsias, photophobia, peripheral visual field loss, and impaired color vision. Despite these symptoms, the eyes may appear relatively quiet externally, with minimal anterior segment inflammation. On examination, mild to moderate vitreous inflammation is often present. The hallmark finding is the presence of multiple cream-colored choroidal lesions with indistinct borders. Cystoid macular edema (CME) is a frequent complication and a major cause of decreased visual acuity. Retinal vasculitis and optic disc edema may also be observed.
Diagnosis is largely clinical but supported by ancillary testing. HLA-A29 testing is highly sensitive and specific. Imaging studies are essential: fluorescein angiography shows early hypofluorescence and late leakage, while indocyanine green angiography often reveals more lesions than are clinically visible. Optical coherence tomography is useful for detecting macular edema. Electroretinography frequently shows reduced photopic and scotopic responses, and visual field testing often demonstrates peripheral constriction. It is important to exclude other causes of posterior uveitis, such as infections (e.g., syphilis, tuberculosis, Lyme disease), sarcoidosis, or intraocular lymphoma.
Management typically involves long-term immunosuppression. Corticosteroids, either systemic or local, are effective for initial control of inflammation, but due to the chronic nature of the disease and the side effects of prolonged steroid use, steroid-sparing immunomodulatory agents are often introduced early. These include medications such as cyclosporine, methotrexate, mycophenolate mofetil, and azathioprine. In refractory cases, biologic agents such as anti–tumor necrosis factor (TNF) therapies or intravenous immunoglobulin may be considered. Local steroid injections may also be used for severe inflammation or macular edema.
The disease course is typically chronic and progressive, with periods of exacerbation and remission. Close, long-term follow-up is essential, including regular monitoring with imaging and functional tests. Prognosis is guarded over time, as visual function may decline even when visual acuity appears relatively preserved. Complications such as cystoid macular edema, epiretinal membrane formation, glaucoma (often secondary to steroid use), choroidal neovascularization, and, rarely, optic nerve atrophy can contribute to vision loss.
- Published on
Ophthalmology – Best’s Vitelliform Macular Dystrophy
Best’s vitelliform macular dystrophy, also known as Best’s disease, is a rare inherited retinal disorder characterized by bilateral involvement of the macula and a distinctive yellow “egg-yolk” lesion. It follows an autosomal dominant inheritance pattern and is caused by mutations in the BEST1 gene on chromosome 11q13, which encodes the bestrophin-1 protein. Although the age of onset is variable, the disease most commonly presents during childhood or adolescence.
The underlying pathophysiology involves dysfunction of bestrophin-1, a calcium-activated chloride channel located in the retinal pigment epithelium (RPE). This dysfunction leads to impaired ion transport and accumulation of lipofuscin between the neurosensory retina and the RPE. Over time, this buildup produces the characteristic vitelliform lesion and contributes to progressive retinal changes.
Patients often present with mild visual symptoms such as blurred vision or metamorphopsia, although some may remain asymptomatic in early stages. A positive family history of retinal dystrophy is an important clue. On examination, the anterior segment is typically normal, while fundus evaluation reveals the classic yellow lesion in the central macula. The disease progresses through several stages, beginning with subtle RPE changes and advancing to the vitelliform “egg-yolk” stage. Later stages may show fragmentation of the lesion (“scrambled egg”), layering of material (pseudohypopyon), and eventual atrophy or scarring. In some cases, complications such as choroidal neovascularization can develop.
Diagnostic testing plays a key role in confirming the diagnosis. A hallmark finding is a normal full-field electroretinogram (ERG) with an abnormal electrooculogram (EOG), reflecting RPE dysfunction. The Arden ratio is typically reduced. Imaging studies such as optical coherence tomography (OCT) demonstrate subretinal deposits and structural changes, while fundus autofluorescence shows increased autofluorescence corresponding to lipofuscin accumulation. Fluorescein angiography may reveal blockage from lesions or leakage if neovascularization is present. Genetic testing can confirm mutations in the BEST1 gene.
There is no specific medical treatment for Best’s disease itself. Management primarily involves observation and regular follow-up with a retina specialist. Patients are monitored for disease progression and complications, particularly choroidal neovascularization. If such complications arise, treatment options include intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy or photodynamic therapy.
The prognosis is generally favorable, with many patients maintaining visual acuity of 20/40 or better for a significant portion of their lives. However, visual outcomes can vary depending on disease progression and the development of complications. Choroidal neovascularization remains the most important cause of vision loss in affected individuals. Genetic counseling is recommended for patients and their families due to the hereditary nature of the condition.
- Published on
Ophthalmology – Benign Conjunctival Lesions
Benign conjunctival lesions represent a diverse group of nonmalignant growths affecting the conjunctiva, including papilloma, Kaposi’s sarcoma, limbal dermoid, sarcoidosis-related nodules, and pyogenic granuloma. These lesions have a low potential for malignant transformation but vary widely in their causes, clinical appearance, and management. While many are asymptomatic, they may produce symptoms due to mass effect or cosmetic concerns.
The epidemiology varies depending on the specific lesion. Kaposi’s sarcoma may involve the ocular adnexa in a subset of patients with systemic disease, particularly in immunocompromised individuals. Sarcoidosis can involve the conjunctiva in a smaller proportion of systemic cases. Limbal dermoids are typically congenital and present early in life, whereas other lesions such as papillomas or pyogenic granulomas may occur at any age depending on underlying risk factors.
Risk factors differ among lesion types. Conjunctival papillomas are associated with human papillomavirus (HPV), often transmitted during childbirth or through direct contact, and may also be influenced by ultraviolet exposure. Kaposi’s sarcoma is strongly linked to immunosuppression, including HIV/AIDS, chemotherapy, organ transplantation, and advanced age. Limbal dermoids are congenital lesions, sometimes associated with syndromes such as Goldenhar syndrome. Sarcoidosis is more common in African American patients and is associated with systemic granulomatous disease. Pyogenic granulomas often arise following ocular surgery, trauma, or chronic inflammation as part of an exaggerated wound-healing response.
The pathophysiology reflects the underlying cause of each lesion. Papillomas result from viral-induced epithelial proliferation, while Kaposi’s sarcoma arises from vascular proliferation driven by human herpesvirus-8. Limbal dermoids are choristomas containing normal tissue in an abnormal location, often including hair follicles and sebaceous glands. Sarcoidosis leads to noncaseating granulomatous inflammation, and pyogenic granulomas represent reactive fibrovascular proliferation following injury or inflammation.
Patients may present with a variety of symptoms, although many lesions are discovered incidentally. When symptomatic, patients may report foreign body sensation, irritation, tearing, itching, photophobia, or blurred vision. Larger lesions can cause mechanical effects such as ptosis, trichiasis, or poor eyelid apposition. A thorough history is important, including immune status, systemic symptoms suggestive of sarcoidosis, prior ocular surgery or trauma, and congenital onset in the case of limbal dermoids.
On examination, the appearance of the lesion often suggests the diagnosis. Papillomas typically appear as pink-red, fleshy, pedunculated or sessile lesions, sometimes with a verrucous surface. Kaposi’s sarcoma presents as a reddish-purple, flat or nodular lesion. Sarcoid lesions are usually yellow or salmon-colored nodules, often located in the inferior conjunctival fornix. Limbal dermoids appear as yellowish-white, well-circumscribed masses near the limbus and may contain fine hairs. Pyogenic granulomas are highly vascular, red, elevated lesions often attached by a stalk. Secondary findings may include conjunctival swelling, corneal irritation, or surface damage.
Diagnosis is primarily clinical but may be supported by laboratory and imaging studies when systemic disease is suspected. For example, HIV testing is indicated in suspected Kaposi’s sarcoma, while serum angiotensin-converting enzyme levels and chest imaging may aid in diagnosing sarcoidosis. Biopsy, either incisional or excisional, is recommended when there is concern for malignancy or when the diagnosis is uncertain.
Management depends on the specific lesion and symptom severity. Many lesions, such as papillomas and pyogenic granulomas, may resolve spontaneously and can be observed initially. Topical treatments, such as steroids for sarcoidosis or lubrication for limbal dermoids, may provide symptomatic relief. Kaposi’s sarcoma is managed primarily with systemic therapy such as highly active antiretroviral therapy in HIV-positive patients. For persistent, symptomatic, or suspicious lesions, surgical excision is often indicated, sometimes combined with adjunctive therapies such as cryotherapy or topical medications.
The prognosis for benign conjunctival lesions is generally excellent. Most lesions remain stable or resolve with appropriate management, although recurrence can occur, particularly after surgical removal. Complications are uncommon but may include scarring, infection, or, in the case of limbal dermoids, residual corneal opacity or refractive error. In some cases, systemic complications may arise depending on the underlying associated condition, emphasizing the importance of a comprehensive evaluation.
- Published on
Ophthalmology – Behçet’s Disease
Behçet’s disease is a multisystem inflammatory disorder characterized by a systemic vasculitis affecting small blood vessels. It classically presents with a triad of recurrent oral aphthous ulcers, genital ulcers, and uveitis, although skin lesions and systemic involvement are also common. The ocular manifestations are particularly important, as they can range from mild anterior uveitis to severe, sight-threatening retinal vasculitis. The disease tends to follow a relapsing-remitting course and can involve multiple organ systems.
Epidemiologically, Behçet’s disease is most prevalent along the historic “Silk Road,” particularly in countries such as Turkey, Japan, the Middle East, and parts of Asia. It most commonly affects young adults between the ages of 25 and 35, although it can occur at any age. While earlier reports suggested a male predominance, more recent data indicate a more equal distribution between sexes. The disease is rare in North America. Genetic predisposition plays a role, with a strong association with the HLA-B51 allele, while environmental or infectious triggers such as streptococcal organisms and viruses have been proposed but not definitively proven.
The pathophysiology involves an abnormal immune response leading to a nonspecific obliterative vasculitis. Dysfunction of lymphocytes and immune regulation results in inflammation and damage to blood vessels throughout the body. This explains the wide range of systemic and ocular manifestations seen in affected patients.
Diagnosis of Behçet’s disease is clinical, as there is no single confirmatory laboratory test. The most widely used criteria require recurrent oral ulcers (at least three times in one year) along with at least two of the following: recurrent genital ulcers, ocular inflammation, skin lesions, or a positive pathergy test. Oral ulcers are the most common feature, occurring in nearly all patients, and appear as painful, well-defined lesions with a red border. Genital ulcers may be painful or painless and often recur. Skin findings include erythema nodosum, acneiform eruptions, and superficial thrombophlebitis.
Ocular involvement occurs in a majority of patients and is a major cause of morbidity. Patients typically present with eye pain, redness, photophobia, and blurred vision. Anterior segment findings include nongranulomatous anterior uveitis, sometimes with a shifting hypopyon, although hypopyon is less common today due to earlier treatment. Posterior segment involvement is more severe and includes retinal vasculitis affecting both arteries and veins, vitreitis, vascular occlusion, and retinal ischemia. These changes can lead to complications such as neovascularization and vision loss. Neuro-ophthalmic findings, including cranial nerve palsies and optic disc edema, may occur in cases with central nervous system involvement.
Evaluation includes a thorough clinical examination and may be supported by laboratory testing. Although routine labs are often nonspecific, tests such as HLA-B51 typing and the pathergy test can support the diagnosis. Imaging studies, particularly fluorescein angiography, are essential in assessing retinal vascular involvement and monitoring disease progression. In cases with suspected neurologic involvement, MRI and cerebrospinal fluid analysis may be required.
Management depends on disease severity and organ involvement. Mild disease may be managed conservatively, but moderate to severe cases—especially those with ocular, neurologic, or vascular involvement—require aggressive immunosuppressive therapy. Systemic corticosteroids are often used initially for rapid control of inflammation, but long-term use necessitates steroid-sparing agents. These include immunosuppressive drugs such as azathioprine, mycophenolate mofetil, cyclosporine, and tacrolimus, as well as cytotoxic agents like cyclophosphamide. Biologic therapies, particularly tumor necrosis factor (TNF) inhibitors such as infliximab and adalimumab, have become increasingly important in controlling severe disease. A multidisciplinary approach involving ophthalmologists, rheumatologists, and other specialists is essential.
Patients with ocular involvement require urgent referral to a uveitis or retinal specialist due to the high risk of vision loss if treatment is delayed. Surgical interventions, such as cataract extraction, may be performed once inflammation is well controlled, while laser photocoagulation may be used to treat retinal neovascularization.
The prognosis of Behçet’s disease has improved significantly with modern immunosuppressive and biologic therapies, although visual outcomes can still be guarded. Without adequate treatment, a high proportion of patients may develop severe visual impairment or blindness. Systemic prognosis is generally favorable in the absence of major complications such as central nervous system involvement or large-vessel disease. Over time, many patients experience longer periods of remission, and disease activity may stabilize after approximately a decade.
Complications primarily relate to chronic inflammation and vascular damage. Ocular complications include cataract, glaucoma, retinal ischemia, neovascularization, vitreous hemorrhage, retinal detachment, and optic nerve damage, all of which can contribute to permanent vision loss.
- Published on
Ophthalmology – Arcus Senilis
Arcus senilis is a common ocular finding characterized by a yellowish-white ring of lipid deposition in the peripheral cornea, separated from the limbus by a narrow clear zone. It is most frequently seen in older adults and is considered a benign, age-related change that does not affect vision or require treatment. In younger individuals, however, the presence of arcus—often termed arcus juvenilis—may indicate underlying systemic conditions such as hyperlipidemia and increased cardiovascular risk.
The prevalence of arcus senilis increases with age, affecting a significant proportion of individuals over 50 years old, with estimates around 65%. It is more commonly observed in men and in individuals of African descent. While aging is the primary risk factor in older patients, early onset arcus is strongly associated with disorders of lipid metabolism, particularly familial hypercholesterolemia, an autosomal dominant condition. In such cases, the development of arcus reflects the duration of lipid abnormalities rather than their severity.
Pathophysiologically, arcus senilis results from the deposition of lipids—including cholesterol, cholesterol esters, triglycerides, and phospholipids—within the corneal stroma. These deposits occur primarily in both superficial (Bowman’s membrane) and deep (Descemet’s membrane) layers, forming characteristic wedge-shaped opacities that eventually merge into a circumferential ring. Despite these structural changes, corneal transparency in the visual axis remains unaffected, which is why vision is preserved.
Clinically, patients are usually asymptomatic and may notice only a change in the appearance of their eyes, sometimes describing a lighter ring around the iris. On examination, the arcus appears as a well-defined peripheral ring with a clear zone adjacent to the limbus. It typically begins as superior and inferior arcs that gradually extend to form a complete 360-degree ring. Slit-lamp examination helps to better visualize the depth and distribution of lipid deposits.
Although arcus senilis itself does not impair vision, its clinical significance lies in its association with systemic disease in younger patients. In individuals under 50 years of age, especially men, it is considered a marker for hyperlipidemia and may be associated with increased risk of coronary artery disease and cardiovascular mortality. In children, arcus may be linked to congenital ocular anomalies or inherited lipid disorders, necessitating further evaluation.
Diagnosis is primarily clinical, but in younger patients, laboratory evaluation including serum lipid profile is essential. Additional cardiovascular assessment may be warranted depending on risk factors, including evaluation for hypertension, diabetes, smoking history, and family history of cardiovascular disease. In some cases, further investigations such as electrocardiography or stress testing may be indicated.
The differential diagnosis includes other peripheral corneal rings or opacities such as the Kayser–Fleischer ring seen in Wilson’s disease, band keratopathy from calcium deposition, limbal girdle of Vogt, Terrien’s marginal degeneration, and corneal changes associated with metabolic disorders like lecithin-cholesterol acyltransferase deficiency. These conditions can usually be distinguished based on clinical appearance, location, associated symptoms, and systemic findings.
Management of arcus senilis itself is not required, as it is a benign and non-progressive condition in older adults. However, in patients younger than 50 years, identification of arcus should prompt evaluation for underlying lipid abnormalities and cardiovascular risk factors. Patient education is important, with reassurance provided to older individuals and appropriate counseling and referral offered to younger patients for systemic evaluation.
The prognosis is excellent in terms of ocular health, as arcus senilis does not affect vision. Its significance lies primarily as a potential clinical marker for systemic disease in younger individuals, where early detection and management of associated conditions can have important long-term health benefits.
Arcus senilis is a common ocular finding characterized by a yellowish-white ring of lipid deposition in the peripheral cornea, separated from the limbus by a narrow clear zone. It is most frequently seen in older adults and is considered a benign, age-related change that does not affect vision or require treatment. In younger individuals, however, the presence of arcus—often termed arcus juvenilis—may indicate underlying systemic conditions such as hyperlipidemia and increased cardiovascular risk.
The prevalence of arcus senilis increases with age, affecting a significant proportion of individuals over 50 years old, with estimates around 65%. It is more commonly observed in men and in individuals of African descent. While aging is the primary risk factor in older patients, early onset arcus is strongly associated with disorders of lipid metabolism, particularly familial hypercholesterolemia, an autosomal dominant condition. In such cases, the development of arcus reflects the duration of lipid abnormalities rather than their severity.
Pathophysiologically, arcus senilis results from the deposition of lipids—including cholesterol, cholesterol esters, triglycerides, and phospholipids—within the corneal stroma. These deposits occur primarily in both superficial (Bowman’s membrane) and deep (Descemet’s membrane) layers, forming characteristic wedge-shaped opacities that eventually merge into a circumferential ring. Despite these structural changes, corneal transparency in the visual axis remains unaffected, which is why vision is preserved.
Clinically, patients are usually asymptomatic and may notice only a change in the appearance of their eyes, sometimes describing a lighter ring around the iris. On examination, the arcus appears as a well-defined peripheral ring with a clear zone adjacent to the limbus. It typically begins as superior and inferior arcs that gradually extend to form a complete 360-degree ring. Slit-lamp examination helps to better visualize the depth and distribution of lipid deposits.
Although arcus senilis itself does not impair vision, its clinical significance lies in its association with systemic disease in younger patients. In individuals under 50 years of age, especially men, it is considered a marker for hyperlipidemia and may be associated with increased risk of coronary artery disease and cardiovascular mortality. In children, arcus may be linked to congenital ocular anomalies or inherited lipid disorders, necessitating further evaluation.
Diagnosis is primarily clinical, but in younger patients, laboratory evaluation including serum lipid profile is essential. Additional cardiovascular assessment may be warranted depending on risk factors, including evaluation for hypertension, diabetes, smoking history, and family history of cardiovascular disease. In some cases, further investigations such as electrocardiography or stress testing may be indicated.
The differential diagnosis includes other peripheral corneal rings or opacities such as the Kayser–Fleischer ring seen in Wilson’s disease, band keratopathy from calcium deposition, limbal girdle of Vogt, Terrien’s marginal degeneration, and corneal changes associated with metabolic disorders like lecithin-cholesterol acyltransferase deficiency. These conditions can usually be distinguished based on clinical appearance, location, associated symptoms, and systemic findings.
Management of arcus senilis itself is not required, as it is a benign and non-progressive condition in older adults. However, in patients younger than 50 years, identification of arcus should prompt evaluation for underlying lipid abnormalities and cardiovascular risk factors. Patient education is important, with reassurance provided to older individuals and appropriate counseling and referral offered to younger patients for systemic evaluation.
The prognosis is excellent in terms of ocular health, as arcus senilis does not affect vision. Its significance lies primarily as a potential clinical marker for systemic disease in younger individuals, where early detection and management of associated conditions can have important long-term health benefits.
- Published on
Ophthalmology – Anterior Basement Membrane Dystrophy
Anterior basement membrane dystrophy (ABMD) is the most common corneal dystrophy and is also known by several names, including map-dot-fingerprint dystrophy, mare’s tail dystrophy, and Cogan’s microcystic dystrophy. It is characterized by abnormalities in the corneal epithelial basement membrane that lead to irregularities of the corneal surface. Clinically, it is most commonly associated with two distinct presentations: recurrent painful corneal erosions and visual disturbance due to an irregular corneal surface, and management differs depending on which presentation predominates.
ABMD is relatively common, affecting up to 10% of the adult population in the United States, with a higher prevalence in women. It typically presents in the fourth or fifth decade of life and may gradually worsen over time. The condition is usually inherited in an autosomal dominant pattern. It may coexist with other ocular surface disorders, such as Fuchs’ endothelial dystrophy, and can be exacerbated by chronic blepharitis.
The underlying pathophysiology involves abnormalities in the epithelial basement membrane, including thickening, reduplication, and extension into the overlying epithelium. This leads to poor adhesion between the epithelium and underlying layers, as well as entrapment of cellular debris within cyst-like structures. These structural abnormalities result in an irregular corneal surface and predispose the epithelium to recurrent breakdown.
Patients typically present in one of two ways. The first is with recurrent corneal erosions, often characterized by sudden onset of pain upon awakening, accompanied by foreign body sensation, tearing, and photophobia. This occurs because the eyelid adheres to the poorly attached epithelium during sleep and disrupts it when opening. The second presentation involves gradual visual decline due to irregular astigmatism from the abnormal epithelial surface, sometimes accompanied by mild irritation.
On examination, findings vary depending on the presentation. In cases of recurrent erosion, there may be a localized area of loose or absent epithelium along with surrounding characteristic changes of ABMD. In cases presenting with visual disturbance, slit-lamp examination reveals classic map, dot, and fingerprint patterns within the corneal epithelium, often over the visual axis, leading to surface irregularity. Diagnostic evaluation includes visual acuity testing and slit-lamp examination, with corneal topography often demonstrating irregular mires and increased surface irregularity. Anterior segment optical coherence tomography can further delineate epithelial and basement membrane abnormalities. A rigid gas-permeable contact lens trial may help confirm that visual symptoms are due to corneal surface irregularity if vision improves significantly with the lens.
The differential diagnosis depends on the clinical presentation. Painful presentations must be distinguished from other causes of ocular surface irritation such as dry eye disease, infectious or chemical keratitis, trauma, and blepharitis. Visual disturbance must be differentiated from other causes of decreased vision, including cataract, macular disease, optic neuropathy, and other corneal pathologies.
Management is tailored to the presenting symptoms. For recurrent erosions, first-line treatment focuses on aggressive lubrication with artificial tears, gels, or ointments, particularly at bedtime, and advising patients to open their eyes slowly upon waking. Hypertonic saline ointments may be used to reduce epithelial edema. Additional measures include punctal occlusion to improve tear retention and therapeutic bandage contact lenses to protect the corneal surface. Topical nonsteroidal anti-inflammatory drugs and cyclosporine may be used to control inflammation and improve tear production.
For cases that are refractory or recurrent, procedural interventions may be considered. These include mechanical debridement of the epithelium with a diamond-dusted burr, ethanol epitheliectomy, or phototherapeutic keratectomy, all of which aim to improve epithelial adherence and reduce recurrence of erosions.
In patients with visually significant disease, treatment focuses on improving the corneal surface. Superficial keratectomy is commonly performed to remove the abnormal epithelium and irregular basement membrane over the visual axis, allowing regeneration of a smoother epithelial surface. Unlike treatment for erosions, aggressive polishing of Bowman’s layer is generally avoided to reduce the risk of scarring. A bandage contact lens is typically placed postoperatively, and topical antibiotics, steroids, and anti-inflammatory medications are used during healing.
Follow-up is based on symptom recurrence and response to treatment, and interventions may be repeated if necessary. The overall prognosis is excellent for both pain and visual symptoms with appropriate management. However, complications such as secondary infection or subepithelial scarring can occur, particularly following surgical intervention.
Anterior basement membrane dystrophy (ABMD) is the most common corneal dystrophy and is also known by several names, including map-dot-fingerprint dystrophy, mare’s tail dystrophy, and Cogan’s microcystic dystrophy. It is characterized by abnormalities in the corneal epithelial basement membrane that lead to irregularities of the corneal surface. Clinically, it is most commonly associated with two distinct presentations: recurrent painful corneal erosions and visual disturbance due to an irregular corneal surface, and management differs depending on which presentation predominates.
ABMD is relatively common, affecting up to 10% of the adult population in the United States, with a higher prevalence in women. It typically presents in the fourth or fifth decade of life and may gradually worsen over time. The condition is usually inherited in an autosomal dominant pattern. It may coexist with other ocular surface disorders, such as Fuchs’ endothelial dystrophy, and can be exacerbated by chronic blepharitis.
The underlying pathophysiology involves abnormalities in the epithelial basement membrane, including thickening, reduplication, and extension into the overlying epithelium. This leads to poor adhesion between the epithelium and underlying layers, as well as entrapment of cellular debris within cyst-like structures. These structural abnormalities result in an irregular corneal surface and predispose the epithelium to recurrent breakdown.
Patients typically present in one of two ways. The first is with recurrent corneal erosions, often characterized by sudden onset of pain upon awakening, accompanied by foreign body sensation, tearing, and photophobia. This occurs because the eyelid adheres to the poorly attached epithelium during sleep and disrupts it when opening. The second presentation involves gradual visual decline due to irregular astigmatism from the abnormal epithelial surface, sometimes accompanied by mild irritation.
On examination, findings vary depending on the presentation. In cases of recurrent erosion, there may be a localized area of loose or absent epithelium along with surrounding characteristic changes of ABMD. In cases presenting with visual disturbance, slit-lamp examination reveals classic map, dot, and fingerprint patterns within the corneal epithelium, often over the visual axis, leading to surface irregularity. Diagnostic evaluation includes visual acuity testing and slit-lamp examination, with corneal topography often demonstrating irregular mires and increased surface irregularity. Anterior segment optical coherence tomography can further delineate epithelial and basement membrane abnormalities. A rigid gas-permeable contact lens trial may help confirm that visual symptoms are due to corneal surface irregularity if vision improves significantly with the lens.
The differential diagnosis depends on the clinical presentation. Painful presentations must be distinguished from other causes of ocular surface irritation such as dry eye disease, infectious or chemical keratitis, trauma, and blepharitis. Visual disturbance must be differentiated from other causes of decreased vision, including cataract, macular disease, optic neuropathy, and other corneal pathologies.
Management is tailored to the presenting symptoms. For recurrent erosions, first-line treatment focuses on aggressive lubrication with artificial tears, gels, or ointments, particularly at bedtime, and advising patients to open their eyes slowly upon waking. Hypertonic saline ointments may be used to reduce epithelial edema. Additional measures include punctal occlusion to improve tear retention and therapeutic bandage contact lenses to protect the corneal surface. Topical nonsteroidal anti-inflammatory drugs and cyclosporine may be used to control inflammation and improve tear production.
For cases that are refractory or recurrent, procedural interventions may be considered. These include mechanical debridement of the epithelium with a diamond-dusted burr, ethanol epitheliectomy, or phototherapeutic keratectomy, all of which aim to improve epithelial adherence and reduce recurrence of erosions.
In patients with visually significant disease, treatment focuses on improving the corneal surface. Superficial keratectomy is commonly performed to remove the abnormal epithelium and irregular basement membrane over the visual axis, allowing regeneration of a smoother epithelial surface. Unlike treatment for erosions, aggressive polishing of Bowman’s layer is generally avoided to reduce the risk of scarring. A bandage contact lens is typically placed postoperatively, and topical antibiotics, steroids, and anti-inflammatory medications are used during healing.
Follow-up is based on symptom recurrence and response to treatment, and interventions may be repeated if necessary. The overall prognosis is excellent for both pain and visual symptoms with appropriate management. However, complications such as secondary infection or subepithelial scarring can occur, particularly following surgical intervention.
- Published on
Ophthalmology – Anophthalmia
Anophthalmia is a rare congenital condition characterized by the complete absence of the globe. It must be carefully distinguished from severe microphthalmia, in which small remnants of ocular tissue may still be present but are only detectable with imaging or histologic evaluation. The condition may occur in isolation or as part of a broader systemic or syndromic disorder. It can affect one eye (unilateral) or both eyes (bilateral), with significant implications for visual development and overall prognosis.
The condition has an estimated incidence of approximately 10–19 per 100,000 newborns. Risk factors include chromosomal abnormalities, congenital syndromes, and intrauterine exposures to teratogenic agents such as radiation, alcohol, thalidomide, retinoic acid, hydantoin, and certain drugs like lysergic acid diethylamide. Although genetic factors are implicated, no single gene defect has been identified as specifically responsible for true anophthalmia. Preventive strategies include prenatal ultrasound screening and avoidance of teratogenic exposures during pregnancy.
Pathophysiologically, anophthalmia results from complete failure of development of the primary optic vesicle during embryogenesis. The etiology may be genetic, environmental, or idiopathic. The condition is often associated with other abnormalities, including midline craniofacial defects and, in some cases, significant developmental delay, particularly when part of a chromosomal or syndromic disorder.
Clinically, patients present with absence of the globe and reduced orbital volume, often resulting in an enophthalmic appearance and small palpebral fissures. Eyelids may appear normal, small, or partially fused, while adnexal structures such as eyelashes, tarsal glands, and the lacrimal system are usually present. A thorough systemic examination is essential to identify associated anomalies, particularly involving the brain and craniofacial structures. Examination of the parents may help differentiate true anophthalmia from severe microphthalmia, especially if features such as coloboma are identified in family members.
Diagnosis is supported by imaging studies such as MRI or CT scans, which confirm the absence of ocular tissue, optic nerve, and extraocular muscles. In cases with associated anomalies, genetic testing including karyotyping or microarray analysis may be indicated. Serial imaging may also be useful in monitoring orbital bone development over time.
The differential diagnosis includes severe microphthalmia, cystic eye, acquired anophthalmia due to trauma or surgery, phthisis bulbi following severe ocular disease, and rare conditions such as cyclopia or synophthalmia. Distinguishing between these entities is important for prognosis and management.
Management is primarily supportive and focuses on promoting normal orbital and facial development, as well as optimizing cosmetic outcomes. In unilateral cases, protection of the remaining functional eye with safety glasses is essential. The use of a scleral shell or conformer helps stimulate growth of the orbit and surrounding tissues. In more severe cases, surgical interventions such as placement of progressively enlarging orbital expanders, dermal fat grafts, or intraorbital balloons may be required to support orbital development.
Long-term care involves regular follow-up with an ocularist to adjust prostheses and monitor orbital growth, especially during the first five years of life when development is most rapid. Monitoring of developmental milestones and school performance is also important, particularly in children with associated systemic abnormalities. Referral to genetic counseling and support services for visual impairment is recommended.
The prognosis varies widely and depends largely on the presence and severity of associated systemic anomalies. Isolated unilateral anophthalmia may have a relatively good functional outcome with appropriate management, whereas bilateral cases or those associated with significant neurologic or systemic abnormalities often carry a more guarded prognosis.
Anophthalmia is a rare congenital condition characterized by the complete absence of the globe. It must be carefully distinguished from severe microphthalmia, in which small remnants of ocular tissue may still be present but are only detectable with imaging or histologic evaluation. The condition may occur in isolation or as part of a broader systemic or syndromic disorder. It can affect one eye (unilateral) or both eyes (bilateral), with significant implications for visual development and overall prognosis.
The condition has an estimated incidence of approximately 10–19 per 100,000 newborns. Risk factors include chromosomal abnormalities, congenital syndromes, and intrauterine exposures to teratogenic agents such as radiation, alcohol, thalidomide, retinoic acid, hydantoin, and certain drugs like lysergic acid diethylamide. Although genetic factors are implicated, no single gene defect has been identified as specifically responsible for true anophthalmia. Preventive strategies include prenatal ultrasound screening and avoidance of teratogenic exposures during pregnancy.
Pathophysiologically, anophthalmia results from complete failure of development of the primary optic vesicle during embryogenesis. The etiology may be genetic, environmental, or idiopathic. The condition is often associated with other abnormalities, including midline craniofacial defects and, in some cases, significant developmental delay, particularly when part of a chromosomal or syndromic disorder.
Clinically, patients present with absence of the globe and reduced orbital volume, often resulting in an enophthalmic appearance and small palpebral fissures. Eyelids may appear normal, small, or partially fused, while adnexal structures such as eyelashes, tarsal glands, and the lacrimal system are usually present. A thorough systemic examination is essential to identify associated anomalies, particularly involving the brain and craniofacial structures. Examination of the parents may help differentiate true anophthalmia from severe microphthalmia, especially if features such as coloboma are identified in family members.
Diagnosis is supported by imaging studies such as MRI or CT scans, which confirm the absence of ocular tissue, optic nerve, and extraocular muscles. In cases with associated anomalies, genetic testing including karyotyping or microarray analysis may be indicated. Serial imaging may also be useful in monitoring orbital bone development over time.
The differential diagnosis includes severe microphthalmia, cystic eye, acquired anophthalmia due to trauma or surgery, phthisis bulbi following severe ocular disease, and rare conditions such as cyclopia or synophthalmia. Distinguishing between these entities is important for prognosis and management.
Management is primarily supportive and focuses on promoting normal orbital and facial development, as well as optimizing cosmetic outcomes. In unilateral cases, protection of the remaining functional eye with safety glasses is essential. The use of a scleral shell or conformer helps stimulate growth of the orbit and surrounding tissues. In more severe cases, surgical interventions such as placement of progressively enlarging orbital expanders, dermal fat grafts, or intraorbital balloons may be required to support orbital development.
Long-term care involves regular follow-up with an ocularist to adjust prostheses and monitor orbital growth, especially during the first five years of life when development is most rapid. Monitoring of developmental milestones and school performance is also important, particularly in children with associated systemic abnormalities. Referral to genetic counseling and support services for visual impairment is recommended.
The prognosis varies widely and depends largely on the presence and severity of associated systemic anomalies. Isolated unilateral anophthalmia may have a relatively good functional outcome with appropriate management, whereas bilateral cases or those associated with significant neurologic or systemic abnormalities often carry a more guarded prognosis.
- Published on
Ophthalmology – Anisometropia
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
Anisometropia is defined as a difference in refractive error between the two eyes and is one of the most common causes of amblyopia. It becomes particularly amblyogenic when the interocular difference exceeds certain thresholds, such as more than 1.50 diopters of hyperopia, more than 1.00 diopter of astigmatism, or more than 6.00 diopters of myopia. Two main forms are recognized: spherical equivalent anisometropia and astigmatic anisometropia. Because of unequal image clarity between the eyes, the brain preferentially uses the clearer image, leading to suppression of the blurrier eye and impaired visual development.
Anisometropia is relatively common, with a prevalence ranging from 1% to 11% of the population. Among affected individuals, approximately 25–60% develop amblyopia. The condition may change during childhood, but larger degrees of anisometropia, particularly greater than 3 diopters, are more likely to persist. Early detection is critical, as the risk of amblyopia increases with age if untreated, with a significant proportion of young children with anisometropia developing amblyopia over time.
Risk factors include prematurity, especially in association with retinopathy of prematurity, as well as congenital conditions such as ptosis, coloboma, cataract, congenital glaucoma, and microphthalmia. Any condition that leads to asymmetric visual input between the eyes in early life can predispose to anisometropia. Although there is no clear inheritance pattern, a family history increases risk, often reflecting the inheritance of underlying ocular conditions rather than anisometropia itself.
The underlying pathophysiology involves unequal visual input to the brain, which disrupts normal binocular visual development. This imbalance leads to suppression of the image from the more defocused eye and reduced stimulation of the corresponding neurons in the visual cortex. Over time, this results in amblyopia, characterized by decreased visual acuity that cannot be explained by structural abnormalities alone. Functional imaging studies have demonstrated reduced activation in the visual cortex and lateral geniculate nucleus corresponding to the amblyopic eye.
Clinically, anisometropia may present with unequal refractive prescriptions between the eyes or unilateral visual impairment. In some cases, it is detected during routine screening, particularly in children who may not report symptoms. A thorough eye examination is essential, including measurement of visual acuity and a complete dilated examination to exclude other causes of reduced vision. Cycloplegic refraction is critical for accurately identifying the degree of refractive difference between the eyes. Reduced contrast sensitivity may also be observed in anisometropic amblyopia.
The differential diagnosis includes any ocular or neurologic condition that can cause unilateral or asymmetric visual impairment, such as retinal disease, optic nerve pathology, or cortical visual disorders. It is also important to consider structural causes of refractive asymmetry, including differences in axial length, corneal curvature, or lens power.
Management focuses on correcting the refractive error and preventing or treating amblyopia. Spectacle correction is the first-line treatment and may alone lead to significant improvement in visual acuity, with many patients showing improvement over several months. In cases where amblyopia persists, additional therapy is required, typically involving occlusion (patching) of the better-seeing eye or pharmacologic penalization with atropine. Both approaches aim to stimulate use of the amblyopic eye and promote visual development. Contact lenses may be preferred in cases of high anisometropia to reduce image size differences (aniseikonia) and improve cosmetic acceptance.
Follow-up is essential to monitor visual improvement and ensure compliance with treatment. Younger children require more frequent monitoring due to the rapid changes in visual development and the risk of amblyopia. Care must also be taken to avoid occlusion amblyopia in the treated eye. Referral for surgical intervention may be necessary if an underlying structural cause such as cataract or ptosis is identified.
The prognosis is generally good with early detection and appropriate treatment. Many patients experience significant improvement in visual acuity with spectacles alone, and further gains can be achieved with amblyopia therapy. However, delayed treatment reduces the likelihood of full recovery, emphasizing the importance of early screening and intervention. Potential complications include persistent amblyopia and, less commonly, iatrogenic visual loss in the better eye due to overtreatment.
- Published on
Ophthalmology – Anisocoria in Children
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
Anisocoria in children refers to a difference in pupil size of 0.5 mm or more between the two eyes. It is relatively common, with physiologic anisocoria accounting for the majority of cases and occurring in approximately 15–30% of the population. In these benign cases, there is no associated ocular or neurologic abnormality. However, anisocoria in children can occasionally indicate underlying pathology, making careful evaluation essential.
The causes of anisocoria range from benign physiologic variation to serious neurologic or ocular disease. Physiologic anisocoria is idiopathic and not associated with any risk factors. Other causes include trauma (ocular or systemic), inflammation such as iritis, meningitis, pharmacologic exposure to mydriatic or miotic agents, and congenital or acquired neurologic conditions. One particularly important cause is Horner syndrome, which may be congenital due to birth trauma or acquired due to neoplasms such as neuroblastoma. Third cranial nerve palsy, whether congenital or acquired, is another critical cause and may result from trauma, infection, tumors, or, rarely in children, aneurysms. Less common causes include Adie’s tonic pupil, pharmacologic dilation, traumatic iris damage, posterior synechiae, and anterior segment dysgenesis.
Pathophysiologically, anisocoria results from dysfunction or imbalance in the pupillary sphincter or dilator muscles, mechanical restriction of the iris, or disruption of the autonomic innervation to the pupil. In some cases, such as physiologic anisocoria, no structural or functional abnormality is identified.
A detailed history is essential in evaluation. Important aspects include the age of onset, duration, history of trauma (including birth trauma), prior surgeries, and associated symptoms such as ptosis, anhidrosis, or facial flushing. Reviewing old photographs can help determine whether the anisocoria is congenital or acquired. Symptoms such as ptosis or abnormal sweating may suggest Horner syndrome, while diplopia or abnormal eye movements may indicate third nerve palsy.
On physical examination, visual acuity is typically normal in physiologic anisocoria but may be reduced in conditions like third nerve palsy or Adie’s pupil due to amblyopia or accommodative dysfunction. Careful pupil examination is crucial. If anisocoria is greater in darkness, the smaller pupil is abnormal, suggesting conditions such as Horner syndrome or physiologic anisocoria. If anisocoria is greater in light, the larger pupil is abnormal, indicating possibilities such as third nerve palsy, Adie’s pupil, traumatic mydriasis, or pharmacologic dilation. Additional findings such as dilation lag, light-near dissociation, segmental iris constriction, iris heterochromia, and eyelid abnormalities can further aid diagnosis. Extraocular motility should also be assessed, as abnormalities may indicate third nerve involvement. A systemic examination, including palpation for masses in the abdomen or neck, is important when a neoplastic cause is suspected.
Diagnostic testing depends on the suspected underlying cause. In suspected Horner syndrome without clear birth trauma, urine testing for vanillylmandelic acid (VMA) and homovanillic acid (HVA) may be performed to screen for neuroblastoma, although imaging is often more sensitive. MRI of the brain, neck, chest, and abdomen is typically recommended when Horner syndrome is suspected. If third nerve palsy is suspected, MRI with magnetic resonance angiography may be indicated. Pharmacologic testing can also aid diagnosis: apraclonidine or cocaine drops for Horner syndrome, hydroxyamphetamine to localize the lesion, and dilute pilocarpine for Adie’s tonic pupil.
Management focuses on identifying and treating the underlying cause rather than the anisocoria itself. Physiologic anisocoria requires no treatment. In Adie’s tonic pupil, dilute pilocarpine may be used to improve symptoms and cosmesis. Posterior synechiae due to iritis may be treated with mydriatic agents and anti-inflammatory therapy. Amblyopia, which may occur in conditions like third nerve palsy or Adie’s pupil, should be managed with refractive correction, patching, or atropine penalization. Cosmetic contact lenses may be considered in older children if appearance is a concern. Urgent referral is required if a neoplasm is suspected, and infants with Adie’s pupil should be evaluated by pediatric neurology to exclude systemic disorders.
Follow-up depends on the underlying cause. Physiologic anisocoria does not require ongoing monitoring. Children with third nerve palsy or Adie’s pupil should be followed to monitor for amblyopia. Suspected but unconfirmed Horner syndrome may require reassessment and repeat testing after several months. Conditions such as anterior segment dysgenesis require monitoring for complications like glaucoma.
The prognosis is excellent for physiologic anisocoria, with no impact on vision or development. For other causes, the outcome depends on the underlying condition. Early identification is critical, particularly in cases associated with serious conditions such as neuroblastoma, where prompt diagnosis can be life-saving.
- Published on
Ophthalmology – Acute Multifocal Placoid Pigment Epitheliopathy (AMPPE)
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
Acute multifocal placoid pigment epitheliopathy (AMPPE) is a rare, acquired inflammatory disorder affecting the retinal pigment epithelium (RPE) and choroid. It typically presents with multiple yellowish-white placoid lesions at the level of the RPE, most often involving the posterior pole and macula. The condition is frequently bilateral, and lesions are often seen in different stages of evolution, with healing characterized by areas of RPE hyperplasia. AMPPE is generally considered a self-limited condition, although it can occasionally be associated with systemic complications.
The exact incidence is unknown due to its rarity. Some genetic associations have been reported, particularly with HLA-B7 and HLA-DR2, suggesting a possible immunologic predisposition. The underlying pathophysiology is thought to involve choroidal vascular compromise, leading to secondary ischemia and inflammation of the RPE. Although the precise etiology remains unclear, approximately one-third of patients report a preceding viral-like illness, supporting the possibility of an immune-mediated or post-infectious mechanism.
Patients typically present with sudden, painless visual loss, which may affect one or both eyes. Visual symptoms can include blurred vision or scotomas. On funduscopic examination, characteristic findings include multiple, flat, yellowish-white lesions at the level of the RPE and choroid, often located in the macular region. These lesions may appear in various stages, with some resolving while others are newly forming. As lesions heal, they leave behind areas of pigmentary change due to RPE alteration.
Fluorescein angiography is helpful in confirming the diagnosis, demonstrating early hypofluorescence of the lesions due to blockage or nonperfusion, followed by late hyperfluorescence as dye leaks into the affected areas. The differential diagnosis includes other inflammatory and infectious chorioretinal diseases such as serpiginous choroiditis, ampiginous chorioretinitis, ocular toxoplasmosis, sarcoidosis, ocular lymphoma, and Vogt-Koyanagi-Harada disease.
Management is typically conservative, as most cases resolve spontaneously without treatment within several weeks. Visual recovery usually occurs over 3 to 4 weeks. In cases where the fovea is involved and vision is significantly affected, a short course of systemic corticosteroids may be considered, although evidence supporting this approach is limited. Patients should be referred to a retinal specialist for confirmation of diagnosis and monitoring.
Close follow-up is important to ensure resolution and to monitor for rare complications. Recurrence is uncommon, and repeated episodes should prompt reconsideration of the diagnosis. A critical but rare complication is cerebral vasculitis, which can be life-threatening; therefore, any associated neurological symptoms such as altered mental status require urgent neurological evaluation. The prognosis is generally favorable, with most patients regaining good visual acuity unless significant RPE damage occurs in the foveal region.
